Amicus Briefs Filed by Health Policy Groups Supporting IRA in AstraZeneca Lawsuit

Public health officials, patient advocacy groups and health scholars have filed amicus briefs supporting the U.S. government as it fights a lawsuit from AstraZeneca claiming the Inflation Reduction Act’s (IRA)drug pricing negotiation provisions are unconstitutional.

Signed into law in August 2022, the IRA allows the government to negotiate prices for 10 of the costliest single-source drugs in Medicare’s Part D program starting this year, eventually building to approximately 60 drugs from Part B and D by 2030, with negotiated prices first taking effect in 2026.

Besides AstraZeneca, Bristol Myers Squibb, Johnson & Jonhson, PhRMA, Merck, Novartis, Boehringer Ingelheim, plus multiple chambers of commerce, have sued HHS with claims that the IRA’s drug pricing provisions are unlawful and are tantamount to government price setting.

Read the AARP briefs here and here.

Read the healthcare and medical experts brief here.

Read the American Public Health Association et al brief here.

Read the economists and scholars brief here.

To read the whole story, click here to subscribe.

Related Topics